Interactions of Ginkgo biloba extract (EGb 761), diazepam and ethyl β-carboline-3-carboxylate on social behavior of the rat

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 2, 1997, Pages 333-339

  Chermat, Raymond ^a   Brochet, Denis ^b   DeFeudis, Francis V ^b   Drieu, Katy ^c  

^a Psypharm SA   (France)

^b Institute for BioScience   (United States)

^c Institut Henri Beaufour   (France)

Author keywords

anxiogenic activity; anxiolytic activity; diazepam; Ginkgo biloba extract (EGb 761); social interaction test

Indexed keywords

ANXIOLYTIC AGENT; BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; DIAZEPAM; GINKGO BILOBA EXTRACT;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SOCIAL BEHAVIOR;

ANIMALS; ANTI-ANXIETY AGENTS; CARBOLINES; DIAZEPAM; DRUG INTERACTIONS; GINKGO BILOBA; HERB-DRUG INTERACTIONS; MALE; MOTOR ACTIVITY; PLANT EXTRACTS; RATS; RATS, WISTAR; SOCIAL BEHAVIOR;

EID: 0031049369     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00298-5     Document Type: Article

References (38)

1. Allard, M. Traitement des troubles du vieillissement et extrait de Ginkgo biloba. De la pharmacologie à la clinique. Presse Méd. 15:1540-1545; 1986.
2. 1A receptor desensitization: Protective effects of Ginkgo biloba extract (EGb 761). Fundam. Clin. Pharmacol. 9:169-174; 1995.
3. Braestrup, C.; Nielsen, M.; Olsen, C. E. Urinary and brain β-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc. Natl. Acad. Sci. U.S.A. 77:2228-2292; 1980.
4. Braquet, P. (Ed.) Ginkgolides: Chemistry, biology, pharmacology and clinical perspectives. Vol. 1. Barcelona: J. R. Prous; 1988.
5. Chatterjee, S. S.; Gabard, B. L.; Jaggy, H. E. W. Pharmaceutical compositions containing bilobalid for the treatment of neuropathies. U. S. Patent No. 2,571,407; 1986.
6. Chopra, K.; Singh, M.; Gupta, S.; Ganguly, N. K. Involvement of oxygen free radicals in the action of BN 52021 (PAF antagonist) to limit myocardial infarct size. Meth. Find. Exp. Clin. Pharmacol. 15;437-445; 1993.
7. Clostre, F.; DeFeudis, F. V. (Eds.) Advances in Ginkgo biloba extract research: Vol. 3. Cardiovascular effects of Ginkgo biloba extract (EGb 761). Paris: Elsevier; 1994.
8. Corcoran, P. C.; Tse, S. S.; Katz, N. M.; Wang, Y.; St. Louis, J. D.; Foegh, M. L.; Analouei, A. R.; Wallace, R. B. Reduction of conjugated dienes in lung transplantation: Effect of BN 52021. Ann. Thorac. Surg. 56:1279-1284; 1993.
9. DeFeudis, F. V. Ginkgo biloba extract (EGb 761): Pharmacological activities and clinical applications. Paris: Elsevier; 1991; 187 pp.
10. Eckmann, F.; Schlag, H. Kontrollierte Doppelblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskulärer Insuffizienz. Fortschr. Med. 100:1474-1478; 1982.
11. File, S. E. The use of social interaction as a method of detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Meth. 2:219-238; 1980.
12. File, S. E. Animal models for predicting clinical efficacy of anxiolyticdrugs: Social behaviour. Neuropsychobiology, 13:55-62; 1985.
13. File, S. E. The contribution of behavioral studies to the neuropharmacology of anxiety. Neuropharmacology, 26:877-886; 1987.
14. File, S. E.; Baldwin, H. A. Effects of β-carbolines in animal models of anxiety. Brain Res. Bull. 19:293-299; 1987.
15. File, S. E.; Hyde, J. R. G. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquillizers and stimulants. Pharmacol. Biochem. Behav. 11:65-69; 1979.
16. File, S. E.; Lister, R. G. Interactions of ethyl-β-carboline-3- carboxylate and RO 15-1788 with CGS 8216 in an animal model of anxiety. Neurosci. Lett. 39:91-94; 1983.
17. File, S. E.; Lister, R. G.; Nutt, D. G. The anxiogenic action of benzodiazepine antagonists. Neuropharmacology, 21:1033-1037; 1982.
18. File, S. E.; Pellow, S. The anxiogenic action of FG 7142 in the social interaction test is reversed by chlordiazepoxide and RO 15-1788 but not by CGS 8216. Arch. Int. Pharmacodyn. 271:198-205; 1984.
19. File, S. E.; Vellucci, S. V. Studies on the role of ACTH and of 5-HT in anxiety, using an animal model. J. Pharm. Pharmacol. 30:105-110; 1978.
20. Halama, P.; Bartsch, G.; Meng, G. Hirnleistungsstörungen vaskulärer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo-biloba-Extrakt. Fortschr. Med. 106:408-412; 1988.
21. Heiss, W. D.; Zeiler, K. Medikamentöse Beeinflussung der Hirndurchblutung. Pharmakotherapie, 1:137-144; 1978.
22. Hofferberth, B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacol. 9:215-222; 1994.
23. Janssens, D.; Michiels, C.; Delaive, E.; Eliaers, F.; Drieu, K.; Remacle, J. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem. Pharmacol. 50:991-999; 1995.
24. Kleijnen, J.; Knipschild, P. Ginkgo biloba for cerebral insufficiency. Br. J. Clin. Pharmacol. 34:352-358; 1992.
25. Költringer, P.; Eber, O. Die kollageninduzierte Thrombozyten-aggregation unter parenteraler Ginkgo-biloba-Therapie. Wien. Med. Wschr. 5:92-94; 1989.
26. Leroy, H.; Salaün, P.; Chovelon, R.; Bouilloux, E. Approche clinique et psychométrique en gériatrie. Méthodes d'études et choix d'une thérapeutique. Vie Médicale, 28:2513-2519; 1978.
27. Middleton, E., Jr. The flavonoids. Trends Pharmacol. Sci. 5:335-338; 1984.
28. Nakanishi, K.; Habaguchi, K. Biosynthesis of ginkgolide B, its diterpenoid nature, and origin of the tert-butyl group. J. Am. Chem. Soc. 93:3546-3547; 1971.
29. Oliver, C.; Guillaume, V.; Héry, F.; Bourhim, N.; Boiteau, K.; Drieu, K. Effect of Ginkgo biloba extract on the hypothalamo-pituitary-adrenal axis and plasma catecholamine levels in stress. Eur. J. Endocrinol. 130 (Suppl. 2): 207 (Abstr. No. P3.072); 1994.
30. Pietri, S.; Culcasi, M.; Chalier, F.; Seguin, J.; d'Arbigny, P.; Drieu, K.; Tordo, P. Cardioprotective effects of terpenic constituents of Ginkgo biloba extract (EGb 761), ginkgolides A and B, and bilobalide. Effects of low doses administered in vitro or in vivo. J. Mol. Cell. Cardiol. 26: Abstr. No. 2.26; 1994.
31. Pietta, P. G.; Gardana, C.; Mauri, P. L.; Maffei-Facino, R.; Carini, M. Identification of flavonoid metabolites after oral administration to rats of a Ginkgo biloba extract. J. Chromatog. B, 673: 75-80; 1995.
32. Porsolt, R. D.; Martin, P.; Lenègre, A.; Fromage, S.; Drieu, K. Effects of an extract of Ginkgo biloba (EGb 761) on learned helplessness and other models of stress in rodents. Pharmacol. Biochem. Behav. 36:963-971; 1990.
33. Rapin, J. R.; Lamproglou, I.; Drieu, K.; DeFeudis, F. V. Demonstration of the anti-stress activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen. Pharmacol. 25:1009-1016; 1994.
34. Rapin, J. R.; Provost, P.; DeFeudis, F. V.; Drieu, K. Effects of repeated treatments with an extract of Ginkgo biloba (EGb 761) and bilobalide on glucose uptake and glycogen synthesis in rat erythrocytes: An ex vivo study. Drug. Dev. Res. 31:164-169; 1994.
35. Spinnewyn, B.; Blavet, N.; Drieu, K. Effect of Ginkgo biloba extract (EGb 761) on oxygen consumption by isolated cerebral mitochondria. In: Christen, Y.; Courtois, Y.; Droy-Lefaix, M. T., eds. Advances in Ginkgo biloba Extract Research. Vol. 4. Effects of Ginkgo biloba Extract (EGb 761) on Aging and Age-Related Disorders. Paris: Elsevier; 1995:17-22.
36. Warburton, D. M. Psychopharmacologie clinique de l'extrait de Ginkgo biloba. Presse Méd. 15:1595-1604; 1986.
37. Weinges, K.; Bähr, W. Bilobalid A, ein neues Sesquiterpen mit tert.-Butyl-Gruppe aus den Blättern von Ginkgo biloba L. Liebigs Ann. Chem. 724:214-216; 1969.
38. Wesnes, K.; Simmons, D.; Rook, M.; Simpson, P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology, 2:159-169; 1987.